Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Nilotinib in Ph+ CML or ALL
NCT01914484Phase 2Completed
- Sponsor
- University Health Network
- Start
- Aug 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by University Health Network. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01914484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01914484.